Introduction
A previous paradigm was that patients with severe aortic stenosis (AS) and preserved left ventricular ejection fraction (LVEF) should necessarily have a high transvalvular gradient. However, we previously reported that a substantial proportion of patients with severe AS on the basis of aortic valve area (AVA) (i.e.≤1.0 cm 2 and indexed AVA ≤ 0.6 cm 2 /m 2 ) may develop a restrictive physiology and myocardial dysfunction resulting in lower LV outflow and thus often lower than expected transvalvular gradients despite the presence of a preserved LVEF, and this clinical entity was labelled 'paradoxical' low-flow (PLF) AS. Several studies reported that patients with PLF AS have a 40-50% lower referral to aortic valve replacement (AVR) compared with those with the more classical normal-flow (NF), high-gradient pattern of AS, likely due to underestimation of stenosis severity in light of the relatively low gradient. 1 -3 Yet, these patients generally have worse prognosis compared with those with NF and high gradient. 1,2,4,5 A sub-study from the SEAS trial, however, suggested that patients with PLF AS have similar outcomes compared with those with moderate AS and NF. 6 Hence, there are some uncertainties and debates regarding the actual severity of the stenosis and the relevance of AVR in the subset patients with PLF low-gradient (PLF-LG) AS. The weight of the valve explanted at the time of AVR has been proposed as a flow-independent marker that can be used a posteriori to corroborate stenosis severity. 7, 8 The objectives of this study were thus: (i) to determine the most appropriate cut-point values of the aortic valve weight (AVW) to identify haemodynamically severe stenosis in men and women; (ii) to compare the AVW in patients with PLF-LG AS vs. those with normal flow and high gradient (NF-HG), i.e. patients with known severe AS; and (iii) to assess AS severity of patients with PLF-LG AS with the use of the AVW.
Methods
Among 250 consecutive patients undergoing AVR (Cohort A), we analysed the clinical, Doppler-echocardiographic, natriuretic peptides, and AVW data in patients with PLF-LG and patients with NF-HG. The primary indication for surgery was the presence of severe AS documented by an AVA ≤ 1.0 cm 2 and indexed AVA ≤ 0.6 cm 2 /cm 2 . Patients with a history of rheumatic disease, endocarditis, and inflammatory diseases as well as patients with aortic valve regurgitation, mitral valve regurgitation, or stenosis grade . mild were excluded.
We also analysed the Doppler-echocardiographic and AVW data in a group of 150 non-consecutive patients (Cohort B) with moderate or severe AS, normal LVEF, and NF undergoing AVR + coronary artery bypass graft surgery. This cohort served as a reference group to determine the optimal cut-point values of AVW for the identification of haemodynamically severe AS.
Clinical data
Clinical data included age, gender, documented diagnosis of hypertension [patients receiving antihypertensive medications or having known, but untreated, hypertension (blood pressure ≥140/90 mm Hg)], obesity (body mass index ≥30 kg/m 2 ), dyslipidaemia (patients receiving cholesterol lowering medication or, in the absence of such medication, documentation of plasma LDL cholesterol level .6.2 mmol/L), diabetes (fasting glucose ≥7 mmol/L), and coronary heart disease (history of myocardial infarction, coronary artery stenosis on preoperative, or previous coronary angiography). The aortic valve phenotype (i.e. bicuspid vs. tricuspid) was assessed by the surgeon at the time of AVR.
Laboratory data
Blood samples were drawn before surgery and plasma NT pro-BNP was determined by a commercially available enzyme-linked immunosorbent assay (USCN Life Science Inc., Wuhan, China). Creatinine was also measured. 
Weight of explanted aortic valves
Each valve excised at the time of surgery was analysed by one of three pathologists. As part of an ongoing research protocol (PROGRESSA Study, ClinicalTrials.gov Identifier: NCT01679431), two cusps (or one cusp if bicuspid valve) were placed in a container filled with HEPES solution and one cusp was placed in RNA later (Ambion Inc., Austin, TX, USA) for subsequent analyses. The cusps and small fragments (if any) in HEPES solution were removed from the container, placed on absorbing paper, and then weighed the same laboratory scale that has an accuracy of +0.01 g. The weight of the cusp placed in RNA later was obtained by subtracting the known weight of the empty containerand RNA later solution from the measured total weight of the container + solution + cusp. The total AVW was then determined by adding the weights of the cusps/fragments in HEPES and in RNA later. We used the data of Cohort B to determine the optimal cut-point values of AVW to identify severe AS and we then applied these cut-point values in Cohort A to corroborate the severity of AS.
Statistical analysis
Results are expressed as mean + SD, median (interquartile), or percentages when appropriate. Continuous variables were tested for normality by the Shapiro -Wilk test. Aortic valve weight, NT pro-BNP, and creatinine were not normally distributed. We used a natural logarithm transformation to normalize AVW and NT pro-BNP. Differences between NF-HG and PLF-LG groups were analysed with the use of t-test or Wilcoxon rank sum test for continuous variables as appropriate, and the Chi-square test or the Fisher exact tests for categorical variables as appropriate. All subsequent analyses of AVW or NT pro-BNP as continuous variables were performed with the use of logarithm-transformed variables. The relationship between AVW and echocardiographic parameters of stenosis severity was assessed with the use of the Pearson correlation coefficient. Receiver operating characteristic (ROC) curves were used to determine the best cut-point values of AVW to identify severe AS. A P-value ,0.05 was considered statistically significant. Statistical analyses were performed with the use of JMP 9.0.0 software.
Results Preoperative data (Cohort A)
There was no difference in baseline clinical characteristics between the NF-HG and PLF-LG groups, except for the prevalence of dyslipidaemia and coronary artery disease that were higher in PLF-LG patients ( Table 1) . Notwithstanding a normal LVEF, stroke volume and flow rate were lower in the PLF-LG patients than in the NF-HG patients. Patients in the PLF-LG group also had smaller LV end-diastolic volume index and LV mass index. As expected, patients in the PLF-LG group had lower gradients despite a similar AVA and indexed AVA compared with patients in the NF-HG group. The valvulo-arterial impedance was higher in the PLF-LG group than in the NF-HG group ( Table 1) . Although they had a lower gradient, patients in PLF-LG had a similar (P ¼ 0.82) level of NT pro-BNP compared with those in the NF-HG group [863 (584-1224) vs. 778 (535-1295); respectively], even after adjustment for coronary artery disease and creatinine level (P ¼ 0.21).
Operative data (Cohort A)
The AVW was similar (P ¼ 0.28) in patients who underwent concomitant CABG [2. The proportion of patients with bicuspid aortic valve was higher (P ¼ 0.003) in the NF-HG group (42%) than in the PLF-LG group (15%) ( Table 1) .
The AVW was significantly (P ¼ 0.02) higher in the NF-HG group compared with the PLF-LG group but with important overlap between the two groups (Table 1 and Figure 2A Figure 2B ). After adjustment for gender (P , 0.0001) and bicuspid phenotype (P ¼ 0.001), the AVW was similar in the NF-HG and PLF-LG groups (P ¼ 0.16). Furthermore, NT pro-BNP levels were similar in the PLF-LG vs. NF-HG groups in the whole cohort as well as in the subsets of men and women ( Figure 3) .
Identification of severe aortic stenosis with the use of aortic valve weight (Cohort B)
The AVW correlated with the parameters of stenosis severity in the whole Cohort B (n ¼ 150) as well as in men (n ¼ 103) and women (n ¼ 47) (all r ≥ |0.40|; all P ≤ 0.0002) ( Table 2) . Table 3 presents the area under the ROC curve (AUC) for the AVW as well as the best cut-point values and their sensitivity and specificity to differentiate severe from moderate AS. The best accuracy to identify severe AS was obtained with an AVW ≥2.0 g for men and ≥1.2 g for women. 
Confirmation of severe aortic stenosis based on aortic valve weight (Cohort A)
When applying the cut-off values of AVW predetermined in Cohort B to the patients of Cohort A, 19 (70%) of PLF-LG patients and 63 (86%) of NF-HG patients had evidence of severe AS on the basis of AVW (P ¼ 0.08) (Figure 4 ). When this analysis was dichotomized by gender, the percentage of severe AS was 89% in men with NF-HG vs. 65% in men with PLF-LG (P ¼ 0.03) and 81% in women with NF-HG vs. 80% in women with PLF-LG (P ¼ 0.92) (Figure 4 ).
Discussion
The main findings of this study are: (i) patients with PLF-LG AS have lower AVW compared with patients with NF-HG. However, after adjustment for gender and bicuspid valve phenotype, the difference between the two groups is no longer significant. (2) Among patients with PLF-LG, 70% have evidence of severe AS on the basis of AVW and this percentage is similar to that of patients with NF and high gradient (86%). These findings suggest that the gradient (or peak aortic jet velocity) may underestimate stenosis severity in patients with PLF-LG and may thus lead to underutilization or inappropriate delay of AVR in some patients. The low flow state may indeed result in pseudo-normalization of the transvalvular gradient despite the presence of severe AS. 1, 9 In this regard, the present study reveals that 13% of the patients had a PLF-LG and the analysis of excised valve weight independently corroborated the presence of severe stenosis in 70% of these patients. However, the significant difference in AVW observed in men between PLF LG and NF HG groups, as well as the significant lower proportion of severe AS observed in men (65%) vs. women (80%) according to the cut-off value of AVW suggests that identification of true severe AS may be more difficult in men than in women in the presence of PLF LG. Nevertheless, the results of this study are consistent with the conclusion that a large proportion of patients with PLF-LG have a severe AS, when using AVW as a reference. And these findings thus lend support to the recommendation (Class IIa, Evidence C) included in the 2012 ESC/EACTS guidelines, which states that AVR should be considered in symptomatic patients with PLF-LG AS after careful confirmation of AS severity. 10 The patients with PLF-LG included in this study presented the typical Doppler-echocardiographic features reported in previous studies, 1, 4, 9, 11, 12 including small LV cavity size, reduced arterial compliance, and increased LV global hemodynamic load as reflected by high valvulo-arterial impedance. Other recent studies 1, 4, 11, 12 also revealed that, compared with patients with NF and high gradient, patients with PLF and low-gradient have more myocardial fibrosis and a markedly reduced LV longitudinal systolic function, which is not evidenced by LVEF. All these factors contribute to the reduced LV outflow and transvalvular gradient and to the worse outcomes observed in these patients. 1, 4, 5, 11, 12 The presence of a low gradient in the context of a preserved LVEF may lead to underestimation of AS severity and therefore Valve weight in paradoxical low-flow, low-gradient aortic stenosis underutilization or inappropriate delay of AVR. Yet, several retrospective or prospective studies reported that these patients generally have better survival when treated surgically than conservatively, even after adjustment for differences in the baseline risk profile. 5,9,13 -17 However, a sub-study of the SEAS trial 6 reported that patients with severe AS on the basis of AVA,1.0 cm 2 but having a low gradient (,40 mmHg) despite preserved LVEF have similar outcomes compared with those with moderate AS, thereby suggesting that these patients may not benefit of AVR. As highlighted in subsequent publications, 4, 18 this subset of patients with discordant AVA-gradient findings is highly heterogeneous and includes patients with PLF-LG AS as well as patients with measurements errors, small body size, and/or inconsistency in the AVA/gradient criteria proposed in the guidelines to define severe stenosis. 18 These observations further underline the importance of ruling out measurement errors and making meticulous differential diagnosis when confronted to discordance between AVA (small) and gradient (low) in patients with preserved LVEF. As emphasized in the recent ESC-EACTS guidelines, 10 patients with PLF should receive a particular attention and undergo further investigation to confirm stenosis severity.
The main advantage of the AVW measured at AVR is that it provides a flow-independent measure of stenosis severity. And in this regard, the correlations we obtained between AVW and parameters of stenosis severity in the present study were similar to those reported by Roberts and Ko 7 and the best correlations were obtained with the peak gradient. However, the main limitation of the AVW from a clinical standpoint is that this parameter can only be used a posteriori, i.e. after AVR. Quantification of aortic valve calcification by multidetector computed tomography (MDCT) could be useful to identify the PLF patients who likely have a severe stenosis despite the presence of a low gradient. In this regard, Cueff et al. 19 initially reported that a valve calcium score .1650 Agatston Unit (AU) provides the best accuracy to identify severe AS. However, a recent study also suggested that different cut-point values of MDCT valve calcium scores should be applied in women (≥1274 AU) vs. men (≥2065 AU), 20 which is consistent with the AVW results reported in the present study. A recent multicentre study also demonstrated the usefulness of stress echocardiography for the confirmation of stenosis severity in patients with PLF-LG AS. Further studies are needed to confirm the usefulness of MDCT and stress echocardiography in patients with PLF-LG AS. 21 Lancellotti et al. 4 reported that patients with PLF-LG AS have higher plasma BNP levels compared with those with NF low-gradient but similar levels compared with those with NF high-gradient. Consistently in the present study, there was also no significant difference in the NT-proBNP levels between the PLF-LG and NF-HG groups ( Table 1 and Figure 3 ). This finding might be related to the fact that BNP is secreted in response to myocardial stretch and that for any given level of pressure overload, LV wall tension is generally lower in patients with smaller LV cavities, such as in patients with PLF. Since BNP synthesis is also influenced by LV geometry and function as well as the presence of concomitant hypertension and coronary artery disease, this biomarker may have limited utility to corroborate stenosis severity in patients with PLF-LG AS.
Study limitations
All patients in this study underwent AVR, which necessarily introduced a treatment bias. In particular, the PLF patients referred to AVR are those who had substantial evidence of severe AS on the basis of the different diagnostic tests performed prior to operation. Hence, the patients' baseline characteristics as well as the prevalence of non-severe, i.e. 'pseudo-severe' reported in this study may not necessarily reflect that observed in the general population with PLF-LG AS. The AVW may underestimate the stenosis severity in patients with a small aortic annulus and overestimate the severity in patients with a large annulus. The utilization of different cut-point values of AVW in men vs. women has partially contributed to overcome this limitation. A more robust option would have been to index the AVW for the cross-sectional area of the aortic annulus after excision of the valve. However, the intraoperative measurement of the aortic annulus with an independent sizer was available only in a small proportion of the patients included in this study.
The present study was focused on PLF-LG AS. However, a substantial proportion of patients has a small AVA, a NF but a lowgradient ( Figure 1) . Recent studies suggest that this normal-flow, lowgradient entity is highly heterogeneous and includes patients with measurements errors, small body size, and discordances due to inconsistencies in the guidelines criteria. 22 -24 These studies also suggest that this entity is generally associated with better prognosis compared with PLF-LG AS. Nonetheless, further studies are needed to determine what is the proportion of patients with normalflow, low-gradient AS who really have severe AS and who may thus benefit from AVR.
Conclusion
These AVW data provide evidence that a large proportion of patients with PLF-LG have a severe stenosis and that the gradient may substantially underestimate stenosis severity in these patients. These findings emphasize the importance to correctly identify patients with PLF AS and to confirm stenosis severity in those having a low gradient. A multi-parametric evaluation including all Doppler-echocardiographic parameters of valve function as well as other complementary diagnostic tests, such as stress echocardiography or valve calcium quantification by MDCT might help identify the patients with PLF-LG severe AS who may benefit of AVR. However, further studies are needed to validate this approach and to assess the impact of AVR on the outcome of these patients.
